The autoimmune side of heart and lung diseases

Clinical Reviews in Allergy and Immunology

Volumn 44, Issue 1, 2013, Pages 1-5

  Agmon Levin, Nancy ^a,b   Selmi, Carlo ^c,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Autoantibdoies; Autoimmune; Cardiovascular; Cytokines; Heart; Lung; Smoke

Indexed keywords

CYTOKINE; DNA; FERRITIN; HISTONE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; IRON; MICRORNA; PHOSPHOLIPID ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARDIOLOGIST; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHURG STRAUSS SYNDROME; CONGESTIVE CARDIOMYOPATHY; CROSS REACTION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; HEART DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON METABOLISM; ISCHEMIC HEART DISEASE; LUNG DISEASE; LUNG FIBROSIS; LUNG PARENCHYMA; MEDIATOR; MORBIDITY; PATHOGENESIS; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; RISK FACTOR; SLOVENIA; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TOBACCO;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; HEART DISEASES; HUMANS; LUNG DISEASES; RISK FACTORS;

EID: 84872687592     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8335-x     Document Type: Article

References (90)

1. Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10:248-255
2. Lee CG, Herzog EL, Ahangari F et al (2012) Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-beta1 signaling. J Immunol 189:2635-2644
3. McCormick LL, Zhang Y, Tootell E, Gilliam AC (1999) Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 163:5693-5699
4. Szczeklik W, Jakiela B, Adamek D and Musial J (2011) Cutting edge issues in the Churg-Strauss syndrome. Clin Rev Allergy Immunol. doi: 10.1007/s12016-011-8266-y
5. Bartoloni E, Alunno A, Bistoni O and Gerli R (2011) Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8251-x
6. Fousteri G, Dave A, Morin B, Omid S, Croft M, von Herrath MG (2011) Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun 36:210-220
7. Fae KC, da Silva DD, Oshiro SE et al (2006) Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J Immunol 176:5662-5670
8. Fedoseyeva EV, Zhang F, Orr PL, Levin D, Buncke HJ, Benichou G (1999) De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process. J Immunol 162:6836-6842 (Pubitemid 29309412)
9. Nussinovitch U and Shoenfeld Y (2011) The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8229-8
10. Nussinovitch U and Shoenfeld Y (2010) The Clinical significance of anti-beta-1 adrenergic receptor autoantibodies in cardiac disease. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8228-9
11. Roux-Lombard P, Pagano S, Montecucco F, Satta N and Vuilleumier N (2010) Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8233-z
12. Kalache S, Dinavahi R, Pinney S, Mehrotra A, Cunningham MW, Heeger PS (2011) Anticardiac myosin immunity and chronic allograft vasculopathy in heart transplant recipients. J Immunol 187:1023-1030
13. Fu SM, Deshmukh US, Gaskin F (2011) Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 37:104-112
14. Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65-75
15. Karnabi E, Qu Y, Wadgaonkar R et al (2010) Congenital heart block: identification of autoantibody binding site on the extracellular loop (domain I, S5-S6) of alpha(1D) L-type Ca channel. J Autoimmun 34:80-86
16. Lee TP, Tang SJ, Wu MF, Song YC, Yu CL, Sun KH (2010) Transgenic overexpression of anti-double-stranded DNA autoantibody and activation of Toll-like receptor 4 in mice induce severe systemic lupus erythematosus syndromes. J Autoimmun 35:358-367
17. Somers K, Geusens P, Elewaut D et al (2011) Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 36:33-46
18. Doria A, Zen M, Canova M et al (2010) SLE diagnosis and treatment: when early is early. Autoimmun Rev 10:55-60
19. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M (2011) The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. Autoimmun Rev 10:123-125
20. Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME (2010) Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 9:A259-A266
21. Cantarini L, Imazio M, Brizi MG et al (2010) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol. doi: 10.1007/s12016-010-8219-x
22. Kontaki E, Boumpas DT (2010) Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 35:206-211
23. Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M (2010) Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 9:436-440
24. Etzioni A (2010) Contemporary challenges in human innate immunodeficiency syndromes. Clin rev allergy & immunolo 38:1-2
25. Wollenberg A, Rawer HC, Schauber J (2011) Innate immunity in atopic dermatitis. Clin rev allergy immunol 41:272-281
26. Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO (2010) B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun Rev 9:604-608
27. Benucci M, Manfredi M, Puttini PS, Atzeni F (2010) Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today? Autoimmun Rev 9:801-803
28. Conti F, Perricone C, Ceccarelli F, Valesini G (2010) Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev 9:716-720
29. Saraux A (2010) The point on the ongoing B-cell depleting trials currently in progress over the world in primary Sjogren's syndrome. Autoimmun Rev 9:609-614
30. Behrens M, Smart M, Luckey D, Luthra H, Taneja V (2011) To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. J Autoimmun 37:95-103
31. Arora-Singh RK, Assassi S, del Junco DJ et al (2010) Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J Autoimmun 35:52-57
32. Xiang Y, Peng J, Tai N et al (2012) The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice. J Immunol 188:4747-4758
33. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik MJ (2007) Depletion of B cells in murine lupus: efficacy and resistance. J Immunol 179:3351-3361
34. Fabris M, Quartuccio L, Lombardi S et al (2012) The CC homozygosis of the -174 G > C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev 11:315-320
35. Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat med 17:297-303
36. McKinney EF, Lyons PA, Carr EJ et al (2010) A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat med 16:586-591, 581p following 591
37. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y (2010) Epigenetics and autoimmunity. J Autoimmun 34:J207-J219
38. Ballestar E (2010) Epigenetics lessons from twins: prospects for autoimmune disease. Clin rev allergy immunol 39:30-41
39. Grolleau-Julius A, Ray D, Yung RL (2010) The role of epigenetics in aging and autoimmunity. Clin rev allergy immunol 39:42-50
40. Renaudineau Y (2010) The revolution of epigenetics in the field of autoimmunity. Clin rev allergy immunol 39:1-2
41. McClymont SA, Putnam AL, Lee MR et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186:3918-3926
42. Lee WW, Yang ZZ, Li G, Weyand CM, Goronzy JJ (2007) Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J Immunol 179:2609-2615
43. Trenkmann M, Brock M, Ospelt C, Gay S (2010) Epigenetics in rheumatoid arthritis. Clin rev allergy immunol 39:10-19
44. Zhao S, Long H, Lu Q (2010) Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers, and therapeutic potentials. Clin rev allergy immunol 39:3-9
45. Selmi C, Leung PS, Sherr DH et al (2012) Mechanisms of environmental influence on human autoimmunity: A National Institute of Environmental Health Sciences Expert Panel workshop. J Autoimmun. doi: 10.1016/j.jaut.2012.05.007
46. Miller FW, Alfredsson L, Costenbader KH et al (2012) Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel workshop. J Autoimmun. doi: 10.1016/j.jaut.2012.05.002
47. Germolec D, Kono DH, Pfau JC and Pollard KM (2012) Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS Expert Panel Workshop. J Autoimmun. doi: 10.1016/j.jaut.2012.05.020
48. Miller FW, Pollard KM, Parks CG et al (2012) Criteria for environmentally associated autoimmune diseases. J Autoimmun. doi: 10.1016/j.jaut.2012.05.001
49. Sharma R, Fu SM, Ju ST (2011) IL-2: a two-faced master regulator of autoimmunity. J Autoimmun 36:91-97
50. Baraut J, Michel L, Verrecchia F, Farge D (2010) Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 10:65-73
51. Oo YH, Adams DH (2010) The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun 34:45-54
52. Tiegs G, Lohse AW (2010) Immune tolerance: what is unique about the liver. J Autoimmun 34:1-6
53. Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM (2010) High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J Autoimmun 34:121-126
54. Scheinecker C, Bonelli M, Smolen JS (2010) Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 35:269-275
55. Zandman-Goddard G, Orbach H, Agmon-Levin N et al (2011) Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients. Clin Rev Allergy Immunol. doi: 10.1007/s12016-011-8264-0
56. Sousa GM, Oliveira RC, Pereira MM, Parana R, Sousa-Atta ML, Atta AM (2011) Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev 10:210-213
57. Kherbeck N, Tamby MC, Bussone G et al (2011) The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin Rev Allergy Immunol. doi: 10.1007/s12016-011-8265-z
58. Yan Y, Wang YH, Diamond B (2012) IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells. J Autoimmun 38:1-9
59. Aricha R, Mizrachi K, Fuchs S, Souroujon MC (2011) Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36:135-141
60. Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S (2010) Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun 34:29-37
61. Lisi S, Sisto M, Lofrumento DD et al (2010) Pro-inflammatory role of Anti-Ro/SSA autoantibodies through the activation of Furin-TACE-amphiregulin axis. J Autoimmun 35:160-170
62. Hemdan NY, Birkenmeier G, Wichmann G et al (2010) Interleukin-17- producing T helper cells in autoimmunity. Autoimmun Rev 9:785-792
63. Chan AL, Rafii R, Louie S and Albertson TE (2011) Therapeutic update in idiopathic pulmonary fibrosis. Clin Rev Allergy Immunol
64. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273-288
65. Szekanecz Z, Szanto S, Szabo Z et al (2010) Biologics - beyond the joints. Autoimmun Rev 9:820-824
66. Gualtierotti R, Biggioggero M and Meroni PL (2011) Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome. Clin Rev Allergy Immunol. doi: 10.1007/s12016-011-8268-9
67. de la Torre YM, Pregnolato F, D'Amelio F et al (2012) Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. J Autoimmun 38:J209-J215
68. Saponjski J, Stojanovich L, Djokovic A, Petkovic M, Mrda D (2011) Systemic vascular diseases in the antiphospholipid syndrome. What is the best diagnostic choice? Autoimmun Rev 10:235-237
69. Cervera R, Balasch J (2010) Autoimmunity and recurrent pregnancy losses. Clin rev allergy immunol 39:148-152
70. De Carolis S, Botta A, Santucci S et al (2010) Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin rev allergy immunol 38:116-124
71. Blank M, Shoenfeld Y (2010) Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome. Clin rev allergy immunol 38:141-147
72. Erkan D, Espinosa G, Cervera R (2010) Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 10:74-79
73. Pittschieler S, Wiedermann FJ (2011) Catastrophic antiphospholipid syndrome associated with methicillin-resistant Staphylococcus aureus infection. Autoimmun Rev 10:238
74. Ideguchi H, Ohno S, Uehara T and Ishigatsubo Y (2011) Pregnancy outcomes in Japanese patients with SLE: retrospective review of 55 pregnancies at a university hospital. Clin Rev Allergy Immunol. doi: 10.1007/s12016-011-8269-8
75. Lambrianides A, Carroll CJ, Pierangeli SS et al (2010) Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 184:6622-6628
76. Graham A, Ford I, Morrison R, Barker RN, Greaves M, Erwig LP (2009) Anti-endothelial antibodies interfere in apoptotic cell clearance and promote thrombosis in patients with antiphospholipid syndrome. J Immunol 182:1756-1762
77. Tincani A, Rebaioli CB, Taglietti M, Shoenfeld Y (2006) Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus. Rheumatology 45(Suppl 4):iv8-iv13 (Pubitemid 44446756)
78. Atzeni F, Turiel M, Hollan I et al (2010) Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 9:845-848
79. Sitia S, Tomasoni L, Atzeni F et al (2010) From endothelial dysfunction to atherosclerosis. Autoimmun Rev 9:830-834
80. Turiel M, Sitia S, Atzeni F et al (2010) The heart in rheumatoid arthritis. Autoimmun Rev 9:414-418
81. Ruiz-Irastorza G, Khamashta MA (2009) Managing lupus patients during pregnancy. Best practice & research. Clin Rheumatol 23:575-582
82. Paran D, Fireman E, Levartovsky D et al (2007) Pulmonary dysfunction in systemic lupus erythematosus and anti-phospholipid syndrome patients. Scand J Rheumatol 36:285-290 (Pubitemid 47346914)
83. Zeki AA, Schivo M, Chan AL et al (2010) Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun 34:J327-J338
84. Chandran V, Raychaudhuri SP (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34:J314-J321
85. Invernizzi P (2010) Geoepidemiology of autoimmune liver diseases. J Autoimmun 34:J300-J306
86. Shapira Y, Agmon-Levin N, Shoenfeld Y (2010) Defining and analyzing geoepidemiology and human autoimmunity. J Autoimmun 34:J168-J177
87. Youinou P, Pers JO, Gershwin ME, Shoenfeld Y (2010) Geo-epidemiology and autoimmunity. J Autoimmun 34:J163-J167
88. Arnson Y, Shoenfeld Y, Amital H (2010) Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun 34:J258-J265
89. Anzilotti C, Pratesi F, Tommasi C, Migliorini P (2010) Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 9:158-160
90. Szodoray P, Szabo Z, Kapitany A et al (2010) Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 9:140-143